Floatz logo

Sra-333

Sleep Apnea, Obstructive

Associacao Fundo de Incentivo a PsicofarmcologiaPhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Sleep Apnea, Obstructive cohort.

Asset / SponsorPhaseRating
Adalimumab
Innovaderm Research Inc.
Phase 4BB
Eloralintide
Eli Lilly and Company
Phase 3B
Metformin
Pennington Biomedical Research Center
Phase 1/2CCC
DEXKETOPROFEN
Centre Hospitalier Universitaire de Besancon
N/AD
NEPENTHE
Centre Hospitalier Universitaire de Besancon
N/AD
METAMIZOLE
Centre Hospitalier Universitaire de Besancon
N/AD
Acetazolamide
US Department of Veterans Affairs
N/AD
PROPOFOL
Washington University School of Medicine
N/AD

Same molecule, other indications

Sra-333 is also rated in:

Dementia With Lewy Bodies (DLB)Dormant
BBB
Indicative ·
76 / 100
View asset →
DementiaDormant
BBB
Indicative ·
74 / 100
View asset →
Alzheimer's DiseaseDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →